Aimei Health Technology Co Overview
Valuation check: AFJK's ROE is -9.2%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-9.20%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for AFJK is -9.2%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Aimei Health Technology Co's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, AFJK currently prints -9.2% for ROE, while the sector average sits near -5.68%. That is roughly 61.8% below the sector mean. Large gaps often invite a closer look at Aimei Health Technology Co's growth, margins, and balance sheet.
Return on Equity shows how effectively Aimei Health Technology Co converts resources into returns. At -9.2%, AFJK may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AFJK's ROE (-9.2%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
